← Back to Search

Other

Tovinontrine (CRD-750) for Heart Failure (Cycle-2-PEF Trial)

Phase 2

Recruiting

Research Sponsored by Cardurion Pharmaceuticals, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to week 12

Awards & highlights

Cycle-2-PEF Trial Summary

This trial aims to see if tovinontrine is safe and works better than a placebo in reducing NT-proBNP levels in patients with chronic heart failure.

Who is the study for?

This trial is for adults over 18 with chronic heart failure who have symptoms like shortness of breath or fatigue, signs such as swelling or lung crackles, and a recent history of heart-related hospital visits. They must have certain levels of NT-proBNP in their blood and be on stable heart medication without changes planned post-randomization.Check my eligibility

What is being tested?

The study tests the safety and effectiveness of Tovinontrine (CRD-750) against a placebo in reducing NT-proBNP levels among patients with chronic heart failure who still have normal or near-normal heart pumping function.See study design

What are the potential side effects?

While specific side effects are not listed here, common side effects for treatments like Tovinontrine may include issues like nausea, headache, dizziness, low blood pressure, or potential worsening of heart failure symptoms.

Cycle-2-PEF Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to week 12

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to week 12

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in biomarkers from Baseline to Week 12 - NT-proBNP

Secondary outcome measures

Assessment of pharmacokinetics (PK): PK effect on NT-proBNP

Assessment of pharmacokinetics (PK): PK effect on plasma cGMP

Change in biomarkers at week 12 by treatment group - BNP

+13 more

Cycle-2-PEF Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Tovinontrine (CRD-750)Experimental Treatment1 Intervention

Group II: PlaceboPlacebo Group1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Cardurion Pharmaceuticals, Inc.Lead Sponsor

4 Previous Clinical Trials

492 Total Patients Enrolled

3 Trials studying Heart Failure

480 Patients Enrolled for Heart Failure

Elizabeth Moore, DNPStudy DirectorSenior Director, Clinical Research Cardurion

1 Previous Clinical Trials

400 Total Patients Enrolled

1 Trials studying Heart Failure

400 Patients Enrolled for Heart Failure

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are participating in the entirety of this research study?

"To proceed with the clinical trial, a cohort of 240 individuals meeting the specified criteria is needed. Cardurion Pharmaceuticals, Inc., the sponsor of this research endeavor, will oversee operations from sites such as Cardiology and Medicine Clinic, P.A. in Little Rock, Arkansas and Jacksonville Center for Clinical Research in Jacksonville, Louisiana."

Answered by AI

Is the enrollment for this medical study currently accepting new participants?

"Yes, the information on clinicaltrials.gov confirms that this study is actively seeking volunteers. The trial was initially listed on 3/1/2024 and most recently revised on 3/8/2024. A total of 240 participants will be enrolled at six different locations."

Answered by AI

How prevalent are the sites conducting this research in North America?

"Six research sites are actively enrolling participants for this study, including facilities such as Cardiology and Medicine Clinic, P.A. in Little Rock, Jacksonville Center for Clinical Research in Jacksonville, and Louisiana Heart Center in Covington. This trial is also available at six additional locations."

Answered by AI

Has the FDA officially endorsed Tovinontrine (CRD-750) for medical use?

"Based on the study phase, our team at Power rates Tovinontrine (CRD-750) with a safety score of 2. This indicates that there is existing data supporting its safety but not yet for efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

2024. "Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06215586.

All > Miami > Fort Worth